Click here to subscribe

Disclaimer: This site may include market analysis. All ideas, opinions, alerts and/or forecasts, expressed or implied herein, are for informational purposes only and should not be construed as a recommendation to invest, trade, and/or speculate in the markets. Any investments, trades, and/or speculations made in light of the ideas, opinions, alerts and/or forecasts, expressed or implied herein, are committed at your own risk, financial or otherwise.
Trend Score is our proprietary combination of technical factors reduced to a signal number that allows us to quickly identify stocks on the move. Factors include Moving Averages, Wilder's DMI (ADX), Aroon and MACD. We combine the scores for each of these indicators into a composite score that ranges from 0 to 6 that shows how strongly a stock is trending in a bullish direction.

uniQure N.V. (QURE) jumped $6.10, or 9.4%, to $70.74 on 2.5 million shares Tuesday.  The move, on nearly 5x the stock's average volume, came on no news from the gene therapy company.  The stock, which had a steep ascent from around $28 to just under $70 in the first three months of the year, looks poised to resume the uptrend, as Tuesday's move broke it out above the March double-top.  Watch for $80-85 next.
Few professional investment managers make use of momentum investing, believing that individual stock picking based on an analysis of discounted cash flows and other fundamental factors tends to produce more predictable results, and is a better means of beating index performance over the long term. "As an investment strategy, it’s a thumb in the eye of the 'efficient market hypothesis' (EMH), one of the central tenets of modern finance," to quote a UCLA Anderson Review article, "Momentum Investing: It Works, But Why?" published on Oct. 31, 2018.